Effects of inflammaging on intestinal epithelial cells and aspirin chemoprevention.
炎症对肠上皮细胞的影响和阿司匹林化学预防。
基本信息
- 批准号:10383683
- 负责人:
- 金额:$ 60.03万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-04-05 至 2026-03-31
- 项目状态:未结题
- 来源:
- 关键词:APC geneAddressAdultAdvisory CommitteesAgeAgingAspirinBenefits and RisksBiologicalBiological AssayBiological MarkersBiopsyCancer ModelCell CountCell Culture TechniquesCell physiologyCellsChemopreventionChemopreventive AgentChemoprotective AgentChronic DiseaseClinicalColonColon CarcinomaColonic NeoplasmsColorectal CancerDataDepreciationDevelopmentDinoprostoneDoseDouble-Blind MethodElderlyEnrollmentEpithelialEpithelial CellsEtiologyExperimental ModelsGene Expression ProfileGeneticGuidelinesHumanIncidenceIndividualInflammagingInflammatoryInterventionIntestinal CancerIntestinesLGR5 geneLeadLifeMeasuresMediatingMethodsModelingMucous MembraneMusMutationNon-Steroidal Anti-Inflammatory AgentsOncogenicOrganoidsPathway interactionsPatientsPharmacologyPlacebo ControlPopulationPre-Clinical ModelPreventive serviceProcessProstaglandin InhibitionProstaglandinsRandomized Controlled TrialsReporterReportingResistanceResolutionRoleSecondary toShapesSignal TransductionSmall IntestinesTestingage effectage relatedagedanti-cancerbiomarker developmentcancer biomarkerscolorectal cancer preventioncolorectal cancer riskdisorder preventionepithelial stem cellfetalhuman old age (65+)in vitro Modelin vivointestinal epitheliummortalitymouse modelnovelpre-clinicalpremalignantreceptorregenerativesingle-cell RNA sequencingstem cell functionstem cellstumortumor initiationtumor progressiontumorigenesistumorigenicurinaryyoung adult
项目摘要
PROJECT ABSTRACT
Previous randomized controlled trials (RCT)s demonstrate that low-dose aspirin (LDA, 81-100mg/day) reduces
the risk of colorectal cancer (CRC). The U.S. Preventive Services Task Force (USPSTF) recommends LDA to
prevent CRC in adults aged 50-59. However, a recent RCT among 19,114 older (65+) individuals reported that
initiating LDA late in life had no benefit on CRC incidence and was potentially detrimental for mortality. Because
CRC incidence rises with age, understanding the relationship and functional impact of aging on the
chemopreventive effects of LDA is a high priority. Our working model is that the effect of LDA on the colon
differs in older individuals due to age-related changes in intestinal stem cell (ISC) number and function secondary
to a process of higher basal inflammatory tone, a.k.a. “inflammaging”. Normally, CRC appears to be primarily
driven by oncogenic mutations in Lgr5+ ISCs and aspirin-like NSAIDs appear to preferentially eliminate
premalignant Lgr5+ ISCs. However, our preliminary data demonstrates that old mice (20-22 months [mos]), as
compared to young mice (2-3 mos), have fewer, less regenerative small intestinal Lgr5+ ISCs, which are also
less tumorigenic in an Apc tumor suppressor model. Nonetheless, like humans, aged mice spontaneously
develop a greater number of tumors, indicating that non-Lgr5+ cells are also the origin of intestinal cancers in
aged mice and that these cells are less sensitive to LDA. LDA modulates prostaglandin (PG) levels, including
PGE2. We also find that PGE2 impacts ISC function through its receptor Ptger4 and this signaling can drive ISCs
into a fetal-like state (Hopx+) that is mediated by Hippo/Yap signaling. Thus, in the setting of inflammaging,
elevated PGE2 may irreversibly compromise the colon (cISC) pool leading to compensatory functions within
select cISCs that promote tumorigenesis. Through our double-blind, placebo-controlled RCT, we demonstrated
that modulation of PG tone and inhibition of PG synthesis is central to aspirin’s mode of action. Our central
hypothesis is that aging and age-related processes promote a decrease in the cISC pool (Lgr5+ cISCs) that is
normally sensitive to aspirin chemoprevention. We propose that initiation of LDA earlier in life protects against
this age-related, inflammation-associated, and/or PGE2-mediated damage to the cISC pool. In contrast, with
advancing age there may be a “point-of-no-return” in which initiation of LDA is no longer protective against age-
related changes in the cISC pool. In this proposal, we will expand our existing RCT to examine the impact of
LDA on colonic epithelium at single cell resolution, patient-derived organoids, and urinary PGs in older adults.
We will use novel in vivo preclinical models to dissect the role of inflammaging on PG signaling and LDA on
cISCs. We will then examine the causality of these pathways on colon tumor incidence and progression. These
studies may offer a biological explanation for the unexpected finding of a differential effect of LDA in older adults,
which may influence clinical guidelines or the development of biomarkers to optimize LDA’s risk-benefit profile.
项目摘要
先前的随机对照试验 (RCT) 表明,低剂量阿司匹林(LDA,81-100 毫克/天)可降低
结直肠癌 (CRC) 的风险。美国预防服务工作组 (USPSTF) 建议 LDA
预防 50-59 岁成年人的 CRC。然而,最近一项针对 19,114 名老年人(65 岁以上)的随机对照试验报告称
晚年开始 LDA 对 CRC 发病率没有任何益处,并且可能不利于死亡率。因为
结直肠癌的发病率随着年龄的增长而上升,了解衰老对结直肠癌的关系和功能影响
LDA 的化学预防作用是重中之重。我们的工作模型是 LDA 对结肠的影响
由于肠干细胞(ISC)数量和功能与年龄相关的变化,老年人的情况有所不同
到较高基础炎症张力的过程,又名“炎症”。通常情况下,CRC 似乎主要是
由 Lgr5+ ISC 和阿司匹林样 NSAID 的致癌突变驱动的药物似乎优先消除
癌前 Lgr5+ ISC。然而,我们的初步数据表明,老年小鼠(20-22 个月 [mos]),
与年轻小鼠(2-3 个月)相比,其小肠 Lgr5+ ISC 数量较少且再生能力较差,
在 Apc 肿瘤抑制模型中致瘤性较低。尽管如此,和人类一样,老鼠也会自发衰老
产生更多的肿瘤,表明非 Lgr5+ 细胞也是肠癌的起源
老年小鼠,这些细胞对 LDA 不太敏感。 LDA 调节前列腺素 (PG) 水平,包括
前列腺素E2。我们还发现 PGE2 通过其受体 Ptger4 影响 ISC 功能,并且该信号传导可以驱动 ISC
进入由 Hippo/Yap 信号传导介导的胎儿样状态 (Hopx+)。因此,在炎症的情况下,
PGE2 升高可能会不可逆地损害结肠 (cISC) 池,导致结肠内的代偿功能
选择促进肿瘤发生的cISC。通过我们的双盲、安慰剂对照随机对照试验,我们证明了
调节 PG 张力和抑制 PG 合成是阿司匹林作用方式的核心。我们的中央
假设是衰老和与年龄相关的过程会促进 cISC 库(Lgr5+ cISC)的减少,即
通常对阿司匹林化学预防敏感。我们建议在生命早期开始 LDA 可以防止
这种与年龄相关、炎症相关和/或 PGE2 介导的 cISC 池损伤。相比之下,与
随着年龄的增长,可能会出现一个“不归路”,即 LDA 的启动不再能够预防年龄增长。
cISC 池中的相关更改。在本提案中,我们将扩展现有的随机对照试验(RCT)来研究以下问题的影响:
单细胞分辨率的结肠上皮、患者来源的类器官和老年人尿液 PG 的 LDA。
我们将使用新颖的体内临床前模型来剖析炎症对 PG 信号传导和 LDA 的作用
cISC。然后我们将检查这些途径与结肠肿瘤发生和进展的因果关系。这些
研究可能为 LDA 对老年人的差异效应这一意外发现提供生物学解释,
这可能会影响临床指南或生物标志物的开发,以优化 LDA 的风险收益状况。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Andrew T Chan其他文献
Turning up the heat on colorectal cancer
加大对结直肠癌的研究力度
- DOI:
10.1038/nm.2500 - 发表时间:
2011-10-11 - 期刊:
- 影响因子:50.000
- 作者:
Andrew T Chan - 通讯作者:
Andrew T Chan
ULTRA-PROCESSED FOOD CONSUMPTION AND RISK OF GALLSTONE DISEASE: ANALYSIS OF THREE PROSPECTIVE COHORTS.
超加工食品的消费和胆石病的风险:三个前瞻性队列的分析。
- DOI:
- 发表时间:
2024 - 期刊:
- 影响因子:7.1
- 作者:
Eugenia Uche;Jane Ha;Neha Khandpur;S. Rossato;Yiqing Wang;Long H Nguyen;Ming;E. Giovannucci;Andrew T Chan - 通讯作者:
Andrew T Chan
Andrew T Chan的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Andrew T Chan', 18)}}的其他基金
Effects of inflammaging on intestinal epithelial cells and aspirin chemoprevention.
炎症对肠上皮细胞的影响和阿司匹林化学预防。
- 批准号:
10152090 - 财政年份:2021
- 资助金额:
$ 60.03万 - 项目类别:
Effects of inflammaging on intestinal epithelial cells and aspirin chemoprevention.
炎症对肠上皮细胞的影响和阿司匹林化学预防。
- 批准号:
10597250 - 财政年份:2021
- 资助金额:
$ 60.03万 - 项目类别:
Prebiotic effect of eicosapentaenoic acid treatment for colorectal cancer
二十碳五烯酸治疗结直肠癌的益生元作用
- 批准号:
10406256 - 财政年份:2020
- 资助金额:
$ 60.03万 - 项目类别:
Prebiotic effect of eicosapentaenoic acid treatment for colorectal cancer
二十碳五烯酸治疗结直肠癌的益生元作用
- 批准号:
10620849 - 财政年份:2020
- 资助金额:
$ 60.03万 - 项目类别:
Prebiotic effect of eicosapentaenoic acid treatment for colorectal cancer
二十碳五烯酸治疗结直肠癌的益生元作用
- 批准号:
10161752 - 财政年份:2020
- 资助金额:
$ 60.03万 - 项目类别:
ASPirin in Reducing Events in the Elderly - eXTension
阿司匹林在减少老年人事件中的作用 - eXTension
- 批准号:
10428600 - 财政年份:2019
- 资助金额:
$ 60.03万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 60.03万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 60.03万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 60.03万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 60.03万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 60.03万 - 项目类别:
Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 60.03万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 60.03万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 60.03万 - 项目类别:
EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 60.03万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 60.03万 - 项目类别:
Research Grant














{{item.name}}会员




